CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Ribavirin +1 moredrug
Likely dose
Ribavirin 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01052701
NCT01052701Phase 1Completed
CompareCT.gov

Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment

Johns Hopkins University·interventional·Posted Jan 20, 2010·Updated May 1, 2017

In Brief

A Phase 1 clinical trial evaluating Ribavirin and Ribavirin plus Abacavir (ABC) for Hepatitis C and HIV. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This research is being done to find out whether abacavir (Ziagen®) lowers the levels of ribavirin (Ribapak®) in the body of persons taking these two drugs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, HIV
CountriesUnited States
CollaboratorsGlaxoSmithKline, University of Colorado, Denver

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 20, 2010
Enrollment StartDec 1, 2009
Primary CompletionSep 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.4 years ago

Interventions

Ribavirindrug

Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg) OR Daily RBV alone 600 mg orally every 12 hours (Body Weight \>75 kg)

Ribavirin plus Abacavir (ABC)drug

Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg) OR Daily RBV 600 mg orally every 12 hours (Body Weight \>75 kg) Plus Daily Abacavir 300 mg orally every 12 hours